<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15113">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02115308</url>
  </required_header>
  <id_info>
    <org_study_id>Astellas CMR Tagging</org_study_id>
    <nct_id>NCT02115308</nct_id>
  </id_info>
  <brief_title>Characterization of Changes in Ventricular Mechanics in Response to Lexiscan Stress Using Tagged Cine Cardiac Magnetic Resonance Imaging</brief_title>
  <official_title>Characterization of Changes in Ventricular Mechanics in Response to Lexiscan Stress Using Tagged Cine Cardiac Magnetic Resonance Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Timothy M. Bateman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Saint Luke's Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Saint Luke's Cardiovascular Consultants</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aspire Foundation</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to measure the changes in cardiac function during a Lexiscan
      pharmacologic stress test using cardiac magnetic resonance imaging test.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Strain (ΔR) and/or displacement (Δθ) of normal and abnormal segments</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Strain (ΔR) and/or displacement (Δθ) between segment classifications (normal, reversible, and non-reversible perfusion defects)</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Strain (ΔR) and/or displacement (Δθ) score correlation with flow reserve as measured by PET and/or transmural extent of infarction (TEI) indicated by Late Gadolinium Enhancement (LGE)</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Regadenoson</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regadenoson</intervention_name>
    <arm_group_label>Regadenoson</arm_group_label>
    <other_name>Lexiscan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Myocardial rest/regadenoson stress perfusion PET study within 60 days

          -  Normal rest LVEF (greater than or equal to 50%)

          -  No change in symptoms or treatment between the PET and the MRI study

          -  Willing to consent to the study

          -  Male or female who is either post-menopausal, surgically sterile, or if has a
             childbearing potential, a negative pregnancy test within 2 days prior to the MRI
             study.

        Exclusion Criteria:

          -  Renal dysfunction (estimated glomerular filtration rate &lt; 60 mL/min/1.73m2) within 6
             months

          -  Metallic implants, pacemaker, blood vessel clip (contra-indicated for MRI)

          -  Patient size exceeds MRI bore/table limits: (Max body diameter &gt; 60 cm, weight &gt; 136
             kg)

          -  History of gadolinium contrast allergy or intolerance

          -  Second or third degree AV block

          -  Sinus node dysfunction

          -  Acute myocardial infarction (past 3 months)

          -  Actively wheezing or with acute asthma or bronchospastic attacks requiring changes in
             therapy within the past 30 days

          -  Patients that have experienced a previous hypersensitivity reaction thought to be
             related to regadenoson
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy M Bateman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aspire Foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Staci A Courter, MA</last_name>
    <phone>816-531-2842</phone>
    <phone_ext>107</phone_ext>
    <email>scourter@cvit.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Saint Luke's Health System</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Staci A Courter, MA</last_name>
      <phone>816-531-2842</phone>
      <phone_ext>10</phone_ext>
      <email>scourter@cvit.com</email>
    </contact>
    <investigator>
      <last_name>Joseph Soltys, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>James A Case, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ibrahim Saeed, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Timothy M Bateman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 14, 2014</lastchanged_date>
  <firstreceived_date>April 1, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Aspire Foundation</investigator_affiliation>
    <investigator_full_name>Timothy M. Bateman</investigator_full_name>
    <investigator_title>Medical Director</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Regadenoson</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
